In this work, carvedilol (CARV) was formulated as a microemulsion-loaded oleogel (CARV-MEOG) to enhance its solubility. An HPLC analytical method was developed and validated for assay, content uniformity, and dissolution tests. The mobile phase was composed of a 55:45 (v/v) mixture of 0.015 M phosphate buffer, adjusted to pH 2.7 ± 0.05, and acetonitrile, with a flow rate set at 1.2 mL/min. The separation was conducted using Luna C18 (250 × 4.6) mm, 5 µm column at 35 °C and a wavelength of 240 nm. Injection volumes were 10 µL for assay and content uniformity, and 100 µL for dissolution studies. Validation was carried out in accordance with the ICH Q2(R1) guidelines. The method proved precise, rugged, accurate, selective, specific, and linear across 13.0–30.0 µg/mL for assay and content uniformity, and 0.21–34.0 µg/mL concentration range for dissolution studies. In the assay, forced degradation of CARV, CARV-MEOG, and excipients under stress conditions revealed three major degradants with well-resolved peaks, with RRT of 1.4, 3.7, and 4.2. The molecular masses of the observed degradants were determined using LC/MS, and their chemical structures were proposed. ADMET analysis showed that degradant 1 exhibits altered permeability and genotoxicity (AMES toxic), while degradants 2 and 3 retain similar pharmacokinetics to CARV.